ABVC BioPharmaNASDAQ: ABVC

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

ABVC BioPharma is in the Healthcare sector

ABVC BioPharma is in the Biotechnology industry

ABVC BioPharma is headquartered in United States

ABVC BioPharma initial public offering (IPO) was on 10 November 2004

https://www.abvcpharma.com

No, ABVC BioPharma is not included in the S&P 500 index

No, ABVC BioPharma is not included in the NASDAQ 100 index

No, ABVC BioPharma is not included in the Dow Jones index